INT137222

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2002
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.26
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cellular_component (Sh2d1b2)
Anatomy Link Frequency
neurons 1
Sh2d1b2 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 24 99.62 Very High Very High Very High
positron emission tomography 17 97.04 Very High Very High Very High
Antihistamine 8 73.60 Quite High
corticosteroid 6 71.84 Quite High
imagery 1 64.84 Quite High
Neuropathic pain 3 53.40 Quite High
abdominal pain 2 47.68 Quite Low
headache 2 43.40 Quite Low
dorsal root ganglion 3 38.24 Quite Low
nociceptor 1 25.00 Low Low
Disease Link Frequency Relevance Heat
Targeted Disruption 8 99.32 Very High Very High Very High
Nociception 7 98.50 Very High Very High Very High
Disease 73 98.44 Very High Very High Very High
Emergencies 4 87.44 High High
Anaphylaxis 2 76.04 Quite High
Fabry Disease 45 73.76 Quite High
Respiratory Disease 2 66.76 Quite High
Coagulation Disorder 1 56.92 Quite High
Neuropathic Pain 4 53.40 Quite High
Mucopolysaccharidoses 14 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, there is a subset of female Fabry patients whose disease symptoms are relatively mild or more slowly progressing who currently do not receive ERT.
Neg (not) Positive_regulation (receive) of ERT associated with disease
1) Confidence 0.30 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.34 Pain Relevance 0
galactosidase A (Replagal™) every two weeks (Transkaryotic Therapies, Inc., Cambridge, MA) with fourteen patients receiving ERT and twelve placebo for six months.


Positive_regulation (receiving) of ERT
2) Confidence 0.11 Published 2002 Journal BMC Neurol Section Body Doc Link PMC116601 Disease Relevance 0.17 Pain Relevance 0.18
Wraith and colleagues suggest that patients with severe CNS manifestations be offered ERT for a trial period of 12–18 months, after which time a decision is made whether to continue with the therapy (Wraith et al 2008).
Positive_regulation (offered) of ERT associated with central nervous system
3) Confidence 0.08 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.31 Pain Relevance 0.22
Patients receiving ERT should be monitored carefully during the infusion and for a period afterwards for an infusion related reaction to idursulfase.
Positive_regulation (receiving) of ERT
4) Confidence 0.08 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.09 Pain Relevance 0.20
To explore the function of genes expressed in adult mouse nociceptive neurons, we generated heterozygous knock-in mice expressing the tamoxifen-inducible Cre recombinase construct CreERT2 downstream of the Na(V)1.8 promoter.
Positive_regulation (inducible) of CreERT2 in neurons associated with targeted disruption and nociception
5) Confidence 0.02 Published 2006 Journal Genesis Section Abstract Doc Link 16850455 Disease Relevance 0.35 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox